| Literature DB >> 24929653 |
Emad Fadhal, Eric C Mwambene, Junaid Gamieldien1.
Abstract
BACKGROUND: We have recently shown by formally modelling human protein interaction networks (PINs) as metric spaces and classified proteins into zones based on their distance from the topological centre that hub proteins are primarily centrally located. We also showed that zones closest to the network centre are enriched for critically important proteins and are also functionally very specialised for specific 'house keeping' functions. We proposed that proteins closest to the network centre may present good therapeutic targets. Here, we present multiple pieces of novel functional evidence that provides strong support for this hypothesis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24929653 PMCID: PMC4088370 DOI: 10.1186/1752-0509-8-68
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Graph metrics of human PINs modeled with respect to distance from the centre
| | | | | | | |||||||||
| | | | | | 374 | 4610 | 3464 | 578 | 104 | 14 | 2 | 1 | 1 | Nodes |
| | | | | | 2 | 2 | 1 | 1 | 2 | 1 | Ave degree | |||
| HFPIN | 9448 | 181706 | 13 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | Min degree | |
| | | | | | 531 | 430 | 393 | 14 | 6 | 2 | 2 | 2 | 1 | Max degree |
| | | | | | 0 | 173 | 653 | 307 | 56 | 12 | 1 | 0 | 1 | # quills |
| | | | | | 431 | 3527 | 1929 | 206 | 38 | 4 | | | | Nodes |
| | | | | | 2 | 2 | 3 | | | | Ave degree | |||
| HSN | 6291 | 62737 | 11 | 1 | 1 | 1 | 1 | 1 | 1 | | | | Min degree | |
| | | | | | 451 | 362 | 89 | 11 | 9 | 5 | | | | Max degree |
| | | | | | 4 | 404 | 757 | 133 | 20 | 2 | | | | # quills |
| | | | | | 542 | 6011 | 3352 | 367 | 61 | 4 | 1 | 1 | 1 | Nodes |
| | | | | | 2 | 2 | 1 | 2 | 2 | 1 | Ave degree | |||
| CN | 10573 | 210689 | 13 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | Min degree | |
| | | | | | 590 | 431 | 394 | 12 | 6 | 2 | 2 | 2 | 1 | Max degree |
| 1 | 339 | 831 | 212 | 40 | 3 | 0 | 0 | 1 | # quills | |||||
Functional specialization of HFPIN zones defined by distance from the network centre
| Signal transduction | 38.1 | 26.4 | - | - | - |
| Immune system | 31.3 | 8 | 5.1 | - | - |
| Hemostasis | 18.4 | 5.9 | 2.5 | - | - |
| Disease | 17.5 | 9.1 | 4.4 | - | - |
| Gene Expression | 7.9 | 8.8 | 11.9 | - | - |
| Metabolism | 10.7 | 9.1 | 8.7 | 11.3 | 16.3 |
| Transmembrane transport of small molecules | - | 2 | 2.5 | 3.9 | 13.4 |
| Metabolic pathways | 2.4 | 4.8 | 6.7 | 12.7 | 25 |
Percentages indicate proportion of proteins in a zone belonging to the specific functional class.
Functional specialization of HSN zones defined by distance from the network centre
| Signal transduction | 40.6 | 21.1 | 9.3 | 16 |
| Immune system | 33.6 | 16.2 | 8.4 | - |
| MAPK signalling | 28.9 | 3.5 | - | - |
| Pathways in cancer | 21.4 | 5.7 | - | - |
| Disease | 21 | 10 | 7.2 | 9.8 |
| Hemostasis | 16.5 | 6.9 | 3.3 | - |
| Cell Cycle | 5.3 | 7.6 | 3.4 | - |
| Gene expression | 7.2 | 7.5 | 8.7 | - |
| Metabolism of proteins | - | 4.6 | 4.6 | - |
Percentages indicate proportion of proteins in a zone belonging to the specific functional class.
Summary of cellular function in the central zones of HFPIN
| Signalling pathway | 3186 | 285 (76.2%) | 2141 (46.4%) | 760 (20.8%) |
| Positive signals | 544 | 75 (20%) | 386 (8.3%) | 83 (2.2%) |
| Negative signals | 449 | 57 (15.2%) | 321 (6.9%) | 71 (1.9%) |
| MAPK signalling cascade | 394 | 93 (24.8%) | 258 (5.5%) | 43 (1.1%) |
| Apoptosis signalling pathway | 38 | 13 (3.4%) | 19 (0.4%) | 6 (0.1%) |
| Positive regulation of apoptosis signalling | 22 | 6 (1.6%) | 13 (0.2%) | 3 (0.1%) |
| Negative regulation of apoptosis signalling | 10 | 4 (1%) | 3 (0.06%) | 3 (0.08%) |
Percentages indicate proportion of proteins in a zone belonging to the specific functional class.
Distribution of essential, disease, drug target and classical cancer proteins in HFPIN zones
| 1 | 161 (43%) | 159 (42.5%) | 59 (15.7%) | 15 (4%) | 14 (3.7%) |
| 2 | 1002 (21.7%) | 1184 (25.6%) | 346 (7.5%) | 32 (0.7%) | 42 (0.9%) |
| 3 | 392 (10.7%) | 545 (14.9%) | 77 (2.1%) | 1 (0.02%) | 4 (0.1%) |
| 4 | 55 (9.3%) | 85 (14.4%) | 11 (1.8%) | 1 (0.2%) | 2 (0.3%) |
| 5 | 10 (9.6%) | 19 (18.2%) | 3 (2.8%) | - | - |
| 6 | - | 2 (14.2%) | 1 (7.1%) | - | - |
Distribution of essential, drug target and classical cancer proteins in HSN zones
| 1 | 157 (36.4%) | 69 (16%) | 12 (2.7%) | 12 (2.7%) |
| 2 | 815 (23.1%) | 291 (8.2%) | 33 (0.9%) | 41 (1.1%) |
| 3 | 268 (13.8%) | 103 (5.3%) | 4 (0.02%) | 4 (0.2%) |
| 4 | 29 (14%) | 5 (2.4%) | - | - |
| 5 | 4 (10.5%) | 1 (2.6%) | - | 1 (2.6%) |
HFPIN zone distribution of proteins consistently expressed in cancer samples
| Breast | 330 | 11 (3.3%) | 189 (57.2%) | 121 (36.6%) | 9 (2.7%) | - | - |
| Cervical | 711 | 26 (3.6%) | 425 (59.7%) | 230 (32.3%) | 23 (3.2%) | 7 (0.9%) | - |
| Endometrial | 1515 | 57 (3.7%) | 839 (55.3%) | 514 (33.9%) | 83 (5.4%) | 20 (1.3%) | 2 (0.1%) |
| Fallopian | 1292 | 49 (3.7%) | 715 (55.3%) | 446 (34.5%) | 67 (5.1%) | 14 (1%) | 1 (0.07%) |
| Glioblastoma | 1046 | 38 (3.6%) | 589 (56.3%) | 368 (35.1%) | 44 (4.2%) | 6 (0.5%) | 1 (0.9%) |
| Glioma | 1180 | 40 (3.3%) | 621 (57.7%) | 440 (37.2%) | 63 (5.3%) | 13 (1.1%) | 3 (0.2%) |
| Kidney | 561 | 14 (2.4%) | 331 (59%) | 193 (34.4%) | 23 (4%) | - | - |
| Liver | 715 | 29 (4%) | 402 (56.2%) | 247 (34.5%) | 33 (4.6%) | 4 (0.5%) | - |
| Lung | 532 | 19 (3.5%) | 314 (59%) | 175 (32.8%) | 22 (4.1%) | 2 (0.3%) | - |
| Ovarian | 775 | 26 (3.3%) | 432 (55.7%) | 279 (36%) | 32 (4.1%) | 6 (0.7%) | - |
| Pancreatic | 717 | 30 (4.1%) | 411 (57.3%) | 244 (34%) | 28 (3.9%) | 4 (0.5%) | - |
| Pituitary | 1126 | 37 (3.2%) | 591 (52.4%) | 421 (37.3%) | 61 (5.4%) | 15 (1.3%) | 1 (0.08%) |
| Rectal | 1597 | 69 (4.3%) | 861 (53.9%) | 552 (34.5%) | 90 (5.6%) | 23 (1.4%) | 2 (0.1%) |
HSN distribution of proteins consistently expressed in cancer samples
| Breast | 236 | 12 (5%) | 151 (63.9%) | 70 (29.6%) | 2 (0.8%) | 1 (0.4%) | - |
| Cervical | 533 | 42 (7.8%) | 323 (60.6%) | 157 (29.4%) | 9 (1.6%) | 1 (0.1%) | 1 (0.1%) |
| Endometrial | 1092 | 89 (8.1%) | 647 (59.2%) | 336 (30.7%) | 17 (1.5%) | 2 (0.1%) | 1 (0.09%) |
| Fallopian | 941 | 72 (7.6%) | 563 (59.8%) | 287 (30.4%) | 16 (1.7%) | 2 (0.2%) | 1 (0.1%) |
| Glioblastoma | 767 | 64 (8.3%) | 471 (61.4%) | 216 (28.1%) | 13 (1.6%) | 2 (0.2%) | 1 (0.1%) |
| Glioma | 824 | 35 (8%) | 278 (64%) | 114 (62.2%) | 5 (1.1%) | 1 (0.2%) | 1 (0.2%) |
| Kidney | 434 | 14 (2.4%) | 331 (59%) | 193 (34.4%) | 23 (4%) | - | - |
| Liver | 537 | 45 (8.3%) | 328 (61%) | 155 (28.8%) | 7 (1.3%) | 1 (0.1%) | 1 (0.1%) |
| Lung | 422 | 31 (7.3%) | 260 (61.6%) | 121 (28.6%) | 8 (1.9%) | 2 (0.4%) | - |
| Ovarian | 557 | 39 (7%) | 334 (59.9%) | 174 (31.2%) | 8 (1.4%) | 1 (0.1%) | 1 (0.1%) |
| Pancreatic | 536 | 46 (8.5%) | 332 (61.9%) | 148 (27.6%) | 8 (1.4%) | 1 (0.1%) | 1 (0.1%) |
| Pituitary | 789 | 56 (7%) | 458 (58%) | 253 (32%) | 19 (2.4%) | 2 (0.2%) | 1 (0.1%) |
| Rectal | 1162 | 95 (8.1%) | 677 (58.2%) | 365 (31.4%) | 21 (1.8%) | 3 (0.2%) | 1 (0.8%) |
Figure 1KEGG ‘Pathways in Cancer’. (Zone 1: red, zone 2: orange, zone 3: yellow).
Figure 2KEGG MAPK signalling pathway. (Zone 1: red, zone 2: orange, zone 3: yellow).
Figure 3KEGG Cell-cycle pathway. (Zone 1: red, zone 2: orange, zone 3: yellow).
Figure 4KEGG Apoptosis pathway. Zone 1: red, zone 2: orange.
Functional specialization of CN zones defined by distance from the network centre
| Signal transduction | 43 | 21.6 | - | - |
| Immune system | 32 | 10.9 | 5.4 | - |
| MAPK signalling | 25.8 | 2.3 | - | - |
| Pathway in cancer | 20.7 | 3.5 | - | - |
| Disease | 22.6 | 9.3 | 5.4 | - |
| Hemostasis | 15.9 | 5.3 | - | - |
| Cell Cycle | 5.4 | 5.5 | 3.1 | - |
| Gene expression | 7.8 | 8.3 | 12.5 | - |
| Metabolism | 13.1 | 9.3 | 8.8 | 15.9 |
Percentages indicate proportion of proteins in a zone belonging to the specific functional class.
Distribution of signalling related functions in HFPIN and CN zones
| | ||||||
|---|---|---|---|---|---|---|
| Signalling | 285 (76.2%) | 2141 (46.4%) | 760 (20.8%) | 397 (73.2%) | 2434 (40.4%) | 640 (19%) |
| Positive regulation | 75 (20%) | 386 (8.3%) | 83 (2.2%) | 123 (22.6%) | 393 (6.5%) | 50 (1.4%) |
| Negative regulation | 57 (15.2%) | 321 (6.9%) | 71 (1.9%) | 82 (15.1%) | 344 (5.7%) | 54 (1.6%) |
| MAPK signalling | 93 (24.8%) | 258 (5.5%) | 43 (1.1%) | 139 (25.6%) | 249 (4.1%) | 20 (0.5%) |
Distribution of essential, drug target and classical cancer proteins in CN zones
| 1 | 206 (38%) | 234 (43.2%) | 97 (17.8%) | 17 (3.1%) | 20 (3.6%) |
| 2 | 1084 (18%) | 1279 (21.3%) | 365 (6%) | 32 (0.5%) | 42 (0.6%) |
| 3 | 315 (9.3%) | 415 (12.4%) | 59 (1.7%) | 2 (0.05%) | 4 (0.1%) |
| 4 | 28 (7.6%) | 56 (15.3%) | 3 (0.8%) | 1 (0.2%) | 1 (0.2%) |
| 5 | 2 (3.2%) | 9 (14.8%) | 1 (1.6%) | - | - |
CN distribution of proteins consistently expressed in cancer samples
| Breast | 350 | 24 (6.8 | 224 (64 | 95 (27.1 | 7 (2 | - |
| Cervical | 760 | 43 (5.6 | 496 (65.2 | 203 (26.7 | 16 (2.1 | 2 (0.2 |
| Endometrial | 1644 | 91 (5.5 | 1007 (61.2 | 474 (28.8 | 61 (3.7 | 11 (0.6 |
| Fallopian | 1408 | 71 (5 | 869 (61.7 | 409 (29 | 51 (3.6 | 8 (0.5 |
| Glioblastoma | 1128 | 63 (5.5 | 719 (63.7 | 311 (27.5 | 30 (2.6 | 5 (0.4 |
| Glioma | 1270 | 67 (5.2 | 765 (60.2 | 380 (29.9 | 48 (3.7 | 10 (0.7 |
| Kidney | 593 | 44 (7.4 | 389 (65.5 | 150 (25.2 | 10 (1.6 | - |
| Liver | 769 | 51 (6.6 | 475 (61.7 | 221 (28.9 | 21 (2.7 | 1 (0.1 |
| Lung | 571 | 39 (6.8 | 369 (64.6 | 153 (26.7 | 9 (1.5 | 1 (0.1 |
| Ovarian | 823 | 37 (4.4 | 524 (63.6 | 236 (28.6 | 23 (2.7 | 3 (0.3 |
| Pancreatic | 771 | 44 (5.7 | 483 (62.6 | 223 (28.9 | 21 (2.7 | - |
| Pituitary | 1228 | 60 (4.8 | 738 (60 | 373 (30.3 | 47 (3.8 | 10 (0.8 |
| Rectal | 1753 | 96 (5.4 | 1061 (60.5 | 515 (29.3 | 70 (3.9 | 11 (0.6 |